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Abstract
Purpose To investigate the symptoms and delays in the clinical pathway of bladder cancer (BC).
Methods This is a substudy of a prospective, randomized, multicenter phase III study (FinnBladder 9, NCT01675219) where 
the efficacy of photodynamic diagnosis and 6 weekly optimized mitomycin C instillations are studied in pTa bladder cancer 
with high risk for recurrence. The data of presenting symptoms and critical time points were prospectively collected, and 
the effect of factors on delays was analyzed.
Results At the time of analysis, 245 patients were randomized. Analysis included 131 patients with primary bladder cancer 
and their complete data. Sixty-nine percent had smoking history and 67% presented with macroscopic hematuria. Median 
patient delay (from symptoms to health-care contact) was 7 days. The median general practice delay (from health-care contact 
to urology referral) was 8 days. Median time from urology referral to cystoscopy was 23 days and from cystoscopy to TUR-BT 
21 days. Total time used in the clinical pathway (from symptom to TUR-BT) was 78 days. Current and former smokers had 
non-significantly shorter patient-related and general practice delays compared to never smokers. TUR-BT delay was signifi-
cantly shorter in patients with malignant cytology (16 days) compared to patients with benign cytology (21 days, p = 0.03).
Conclusions Patient-derived delay was short and most of the delay occurred in the referral centers. The majority had macro-
scopic hematuria as the initial symptom. Surprisingly, current and past smokers were more prone to contact the health-care 
system compared to never smokers.
Keywords Diagnosis · Symptoms · Diagnostic delay · Hematuria · Bladder cancer
Introduction
Bladder cancer is the second most common urological 
malignancy and the fourth most common malignancy in 
males (15th in females) in Finland with approximately 1200 
new diagnoses and 300 deaths from the disease in 2015 [1]. 
Important risk factors for bladder cancer are age, male gen-
der, smoking and occupational exposures with cyclic organic 
chemicals [2].
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Macroscopic hematuria is a common symptom of blad-
der cancer and is typically present in 80% of patients [3]. 
Other commonly reported symptoms are urinary frequency, 
urgency or lower urinary tract symptoms. Despite the fact 
that hematuria occurs in both genders, women are less likely 
to be referred to urology [4, 5]. According to some stud-
ies, smokers, especially those with microscopic hematuria, 
undergo less profound assessment [4]. As prolonged hema-
turia assessment, are associated with worse prognosis; a 
prompt diagnostic pathway is important to exclude bladder 
cancer [6, 7].
Recently, the literature of diagnostic delays and hematuria 
assessment has been systematically reviewed [8]. Accord-
ing to earlier prospective studies, patient-related delays are 
rather short, often from 1 to 2 weeks and hospital delay is 
the most significant cause of the total delay [9, 10]. The sig-
nificance of factors related to diagnostic delays in the clinical 
pathway of bladder cancer treatment is in some respects con-
troversial and scarce. The systematic review recommended 
further investigations assessing the effect of age on delays 
[8]. Controversially, only Mansson et al. have found that 
elderly patients had longer delays from initial medical con-
sultation to bladder cancer diagnosis [11], but several other 
studies have reported no consequent differences with varying 
age [9, 12, 13]. Furthermore, Richards et al. observed that 
female gender was associated with sub-optimal hematuria 
assessment. According to large volume studies, female gen-
der is related with delayed hematuria assessment and seems 
to be more likely managed for urinary tract infection (UTI) 
during their evaluation [14].
Although smoking is a strong risk factor for bladder can-
cer, smokers paradoxically appeared less likely to undergo 
comprehensive assessment [8]. Buteau et al. found no dif-
ferences in urology referral rates between smokers and 
never smokers [4], but Elias et al. noticed that smoking was 
associated with an increased likelihood of having no cystos-
copy [15]. However, most studies focus on delays after the 
patient’s first contact with the health-care system and only a 
few have assessed all of these factors related to delays.
The aim of the current study is to investigate the initial 
symptoms and diagnostic delays in the diagnostic pathway 
of bladder cancer patients in the setting of a prospective 
randomized multicenter trial.
Materials and methods
This is a substudy of an ongoing prospective, randomized, 
multicenter phase III study (FinnBladder 9, ClinicalTrials.
gov identifier: NCT01675219). In the study, the efficacy of 
photodynamic diagnosis TUR-BT (vs. white light TUR-BT) 
as well as the efficacy of 6 weekly optimized mitomycin 
C instillations (vs. surveillance) is studied in patents with 
histologically proven pTa low-grade bladder cancer with 
high risk for recurrence (multifocal (no. of tumors ≥ 2) or 
large (≥ 3 cm) primary or recurrent tumors). The “symptoms 
and diagnostic delays” was a preplanned substudy presented 
in the original study protocol. Within this preplanning, the 
specific questionnaires regarding symptoms and delays were 
designed and prospectively collected.
Eligible patients with signed informed consent were ran-
domized after diagnostic cystoscopy at the outpatient clinic 
in each of ten attending institutions. Eligibility was re-eval-
uated after TUR-BT, and if high-grade or invasive (≥ pT1) 
carcinoma or no BC was observed, the patient was excluded 
from the main study. In the current substudy, patients were 
included irrespective of the pathological stage. However, 
those with recurrent tumors were excluded because of unre-
liable data concerning symptom initiation.
After randomization, participants filled a comprehensive 
questionnaire concerning patient characteristics including 
date of birth, gender, smoking status, the type of presenting 
symptoms, and specific dates describing the diagnostic path-
way. Symptoms were categorized as macroscopic hematuria 
or other, which included irritation symptoms, bladder outlet 
obstruction microscopic hematuria, and detection because of 
other investigations. We reported only macroscopic hema-
turia, as the initial symptom had to be experienced by the 
patient and therefore the symptom triggered the contact to 
the health-care system. Most patients had microscopic hema-
turia detected when urinary symptoms were investigated, 
but in three patients asymptomatic microscopic hematuria in 
routine investigations was the sign triggering further investi-
gations. According to patient-reported time points, two dif-
ferent pre-consultation delays were defined—patient delay: 
time from initiation of symptoms to the first contact with the 
health-care system; general practice delay: time from the 
first contact with the health-care system to referral to urolo-
gist consultation and cystoscopy. Additionally, two diagnos-
tic delays were retrieved from patient charts—cystoscopy 
delay: time between urology referral to cystoscopy; TUR 
-BT delay: time between the first cystoscopy and TUR-BT.
Patient characteristics were presented using median and 
interquartile range (IQR) or number [n (%)]. Factors affect-
ing time delays were studied by comparing the medians and 
the statistical significance was analyzed by Mann–Whitney 
U- and Kruskal–Wallis tests.
Results
At the time of data analysis for the current substudy, 245 
patients were randomized to the study. Accrual and exclu-
sion of the study subjects are presented in Fig. 1. Of the ran-
domized patients, 37 had no cancer, 70 had recurrent tumor, 
6 did not complete the questionnaires properly and 1 was 
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regarded as a randomization failure. Therefore, 131 patients 
with primary bladder cancer and with all questionnaire and 
clinical data available were included in the analysis.
The baseline patient and tumor characteristics are shown 
in Table 1. The majority (84%) were men and the mean age 
was 71 years. Of all patients, 69% had smoking history and 
most (67%) presented with macroscopic hematuria. Non-
muscle invasive tumors were present in 90% of patients. 
Excluded patients did not have significantly different char-
acteristics when compared to included ones.
Most patients were referred to urology from public health 
care (n = 71, 54%). Referrals from private physician were 
non-urologic (n = 24, 18%) or urology (n = 3, 2%) referrals. 
Non-urologic referrals from private physicians were mainly 
from occupational health services. Referrals from other 
sources were also reported (n = 15, 12%).
Median patient delay was 7 days. The median general 
practice delay was 8 days. Median time from urology refer-
ral to cystoscopy was 23 days and the TUR-BT delay was 
21 days. Total delay of this clinical pathway from symptom 
to TUR-BT was 78 days.
Pre-consultation delays, i.e., patient and general prac-
tice delays, in different patient sub-groups are presented in 
Table 2 in days with median (IQR). In patient delay, no dif-
ferences were found between age and gender. Current and 
former smokers had non-significantly shorter patient delay 
compared to never smokers.
Similarly, general practice delay showed no differ-
ences between age and gender and also current and for-
mer smokers had also non-significantly shorter general 
practice delay. General practice delay was non-signif-
icantly shorter in patients presenting with hematuria 
(8 days) when compared to patients with other symp-
toms (19 days). Patients referred from public health care 
had shorter general practice delay (7 days) compared 
to patients referred from private health care (17 days), 
although insignificantly. Diagnostic delays, i.e., cystos-
copy and TUR-BT delay, in different patient sub-groups 
are depicted in Table 3.
TUR-BT delay showed no differences between age and 
gender. Current and former smokers had similar TUR-BT 
delay compared to never smokers. TUR-BT delay was 
Fig. 1  Flowchart of the study 
population inclusion process
Trial 
randomization
n = 245
Excluded, no cancer
n = 37
Malignant tumors
n = 208
Excluded, recurrent 
cancers, n=70
Primary malignant 
tumors
n = 138
Final sample
n = 131
Other exclusion, n=7
Randomization 
failure, n=1
Incomplete data, n=6
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significantly shorter in patients with malignant cytol-
ogy (16 days) compared to patients with benign cytology 
(21 days, p = 0.03).
Discussion
In this prospective study, we demonstrate that patient-
derived delay was rather short (7 days) and most of the 
delay occurred in the referral centers. Median time for the 
entire diagnostic pathway was 78 days. Results in our study 
are comparable with a Swedish population study [16]. Most 
patients presented with macroscopic hematuria. Current and 
past smokers were more prone to contact the health-care sys-
tem compared to never smokers. Otherwise, no considerable 
differences were noted in patient delays between different 
patient cohorts.
The most common presenting symptom of bladder can-
cer is visible painless hematuria (up to 80% of all BC 
patients) [3]. Other symptoms related to bladder cancer 
are unexplained urinary frequency, urgency or irritative 
voiding symptoms of the lower urinary tract. In our cohort, 
visible hematuria was the primary symptom in 67% of 
patients, which is lower than that described in other stud-
ies [3]. According to literature, most recent studies con-
cerning symptoms in bladder cancer diagnostics have 
focused on hematuria, and only few studies have evalu-
ated symptoms more widely. Patients with macroscopic 
hematuria promptly seek medical advice and also in medi-
cal care hematuria is recognized as an alarming symptom 
meaning shorter referral wait times [9, 10]. Similarly to 
our study, the recent systematic review assessed that age 
has no impact on hematuria assessment [8]. It seems that 
the influence of gender in hematuria patients is complex 
and widely studied. Female hematuria patients are less 
likely to be referred to urologic evaluation [4, 5] and they 
have more pre-referral consultations [17]. Females are also 
more likely to be managed for UTI during their hematuria 
Table 1  Baseline clinicopathological characteristics
Gender Male N (%) 110 (84)
Age Years Mean (range) 71 (47–94)
Smoking status Current smoker
Former smoker
Never smoker
Unknown
N (%) 26 (20)
64 (49)
22 (17)
19 (14)
Symptoms Hematuria
Other
Not reported
N (%) 88 (67)
26 (20)
17 (13)
Hospital districts Helsinki Univer-
sity Hospital
Turku University 
Hospital
Tampere Univer-
sity Hospital
Oulu University 
Hospital
Kuopio Univer-
sity Hospital
N (%) 28 (21)
19 (15)
37 (28)
19 (15)
28 (21)
T-category pTa
pT1
pT2
N (%) 79 (60)
38 (29)
14 (11)
Concomitant in situ Yes
No
N (%) 10 (8)
121 (92)
Urinary cytology 1–2
3
4–5
N (%) 59 (45)
39 (30)
33 (25)
Table 2  Pre-consultation delays
Patient delay time from initiation of symptoms to the first contact with the health-care system; general 
practice delay time from the first contact with health-care system to referral to urologist consultation and 
cystoscopy
a Current and former smokers
Characteristics Descriptions Patient delay, days
Median (IQR)
General practice 
delay, days
Median (IQR)
Entire cohort All patients 7 (27) 8 (37)
Age < 70
> 70
11 (28)
6 (29)
p = 0.80 7 (42)
10 (37)
p = 0.99
Gender Male
Female
7 (31)
8 (26)
p = 0.99 8 (38)
9 (62)
p = 0.88
Smoking status Smokera
Never
6 (26)
19 (44)
p = 0.46 8 (38)
19 (93)
p = 0.36
Primary symptom Hematuria
Other
9 (29)
6 (18)
p = 0.57 8 (37)
19 (39)
p = 1.00
Primary contact Private health care
Public health care
5 (37)
7 (28)
p = 0.68 17 (34)
7 (44)
p = 0.54
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evaluation [13, 14]. However, a recent study showed that 
gender is not a significant independent predictor of delayed 
hematuria assessment [18], which was in agreement with 
our investigation as we found no correlation between gen-
der and assessment of hematuria.
Patient delay is unique as it is not directly affected by 
medical system or health-care professionals. Most evident is 
that patient delay is rather short and in our investigations the 
median was 7 days, which is in good agreement with previ-
ous studies [9–11]. However, only a few prospective studies 
have assessed the effect of different factors on prolonged 
patient delay, and were unable to expose any clinically rel-
evant factors involved. In a retrospective study, Månsson 
et al. found that hematuria patients had the shortest patient 
delay [11]. In a large prospective study, Wallace et al. have 
widely assessed most of the relevant factors and found corre-
lation only in prolonged delays with higher tumor stage and 
patients with unknown hematuria status [9]. In our study, 
there were no differences in patient delay regarding hema-
turia or tumor status; neither did gender disparities occur, 
which is in agreement with both studies [9, 11]. The impact 
of patient’s smoking history on patient delay has also been 
poorly studied. Only Wallace et al. addressed smoking as a 
risk factor for delayed hematuria assessment and no differ-
ence was found between smokers and never smokers [9]. 
In our study never smokers seemed to be less alarmed than 
current and former smokers when it comes to contacting 
health-care providers. Potentially, smokers are more worried 
about their health, especially when it comes to symptoms 
suggestive of cancer.
General practice delay is more comprehensively studied 
and is measured to be rather short [19, 20]. However, the 
total delay between the onset of hematuria and diagnosis 
of bladder cancer is long and therefore general practice 
delay has a key role between the first contact and defini-
tive diagnosis in specialized medical care. Prompt access 
to urologic investigations and diagnostics is valuable for 
patients with macroscopic hematuria to decrease diagnos-
tic delays and health-care costs [16]. Hematuria patients 
are reported to have shorter general practice delays than 
patients with other symptoms, which was also seen in our 
study [9, 11]. It is probable that general practitioners are 
aware of the significance of hematuria as a sign sugges-
tive of bladder cancer and are, therefore, eager to refer the 
patient to the urologist. Gender disparities did not occur, 
which amplifies earlier investigations and is in agreement 
with a recent study [9, 18]. According to our study, cur-
rent and former smokers are referred to the urologist faster 
than never smokers, which has not been demonstrated 
previously. We assume that general practitioners identify 
smoking as a risk factor for bladder cancer and, therefore, 
are eager to send the patient to a specialist. Surprisingly 
enough, patients referred from private outpatient clinics 
presented with longer pre-consultation delays (i.e., patient 
and general practice delays). No other previous study has 
demonstrated such a phenomenon. Health-care system in 
Finland consists of a large publicly funded health-care 
system and a much smaller private sector. Treatment of 
bladder cancer in Finland is mainly performed in public 
hospitals, but primary diagnosis of bladder cancer can be 
Table 3  Diagnostic delays
TUR -BT transurethral resection of bladder tumor, Cystoscopy delay time between GP referral to cystos-
copy, TUR -BT delay time between the first cystoscopy and TUR-BT, HYKS Helsinki University Hospital 
district, TYKS Turku University Hospital district, TAYS Tampere University Hospital district, OYS Oulu 
University Hospital district, KYS Kuopio University Hospital district
a Current and former smokers
Characteristics Descriptions Cystoscopy 
delay, days
Median (IQR)
TUR-BT delay, 
days
Median (IQR)
Entire cohort All patients 23 (15) 21 (15)
Age < 70
> 70
22 (13)
24 (17)
p = 0.14 20 (14)
22 (14)
p = 0.19
Gender Male
Female
23 (17)
24 (12)
p = 0.70 22 (15)
21 (14)
p = 0.80
Hospital districts HYKS
TYKS
TAYS
OYS
KYS
21 (19)
26 (17)
25 (16)
17 (12)
23 (9)
p = 0.10 26 (11)
19 (19)
21 (15)
20 (22)
22 (21)
p = 0.03
Smoking status Smokera
Never
24 (16)
21 (10)
p = 0.20 21 (15)
23 (18)
p = 0.37
Urine cytology 1–2
3
4–5
23 (18)
23 (14)
21 (10)
p = 0.64 21 (15)
24 (10)
16 (17)
p = 0.03
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made both in private and public health care. A general 
assumption is that this exclusive access to investigations 
in private health care results in shorter diagnostic delays. 
One explanation could be the selection bias. Compar-
ing patients referred from public to private health care, 
those from the private clinics are younger and more fre-
quently never smokers. In addition, although not meas-
ured in the current study, the patient–doctor relationship 
is often longer in the public sector, which may contribute 
to shorter delays.
Only few studies have described the different aspects 
of cystoscopy and TUR-BT delays [8]. Most of the stud-
ies have a limitation of observing only the total diagnostic 
delay instead of reporting also these specific sub-delays, i.e., 
cystoscopy or TUR-BT delay. No differences were found 
in cystoscopy delay and TUR-BT delay when assessing the 
influence of age, gender and smoking status. These find-
ings were in coherence with earlier studies, where the total 
clinical pathway of bladder cancer diagnostic was evaluated 
[9, 18]. Moreover, in our study, no gender differences were 
observed when considering the total delay median (men 80 
vs. women 76) or only those patients presenting macroscopic 
hematuria (men, 76 vs. women 76).
In Finland, urine cytology is performed routinely before 
diagnostic cystoscopy. It is not surprising that positive urine 
cytology (Papa classes 4–5) was associated with shorter 
TUR-BT delay, since urine cytology has high sensitivity in 
high-grade tumors suggestive of urgent treatment. Although 
this direct finding has not been studied previously, it has 
been demonstrated that higher tumor stage and larger tumor 
size are related to shorter delays [9, 11]. There are nota-
ble differences in diagnostic delays between the different 
hospital districts. This is most probably due to the slightly 
different clinical pathway of bladder cancer diagnostics and 
treatment.
The major limitations of our study are the small sam-
ple size, the recall bias in the pre-consultation delays and 
the exclusion rate. A significant amount of patients were 
excluded because of recurring tumors. This was due to the 
patient’s inability to recall pre-consultation delays before the 
initial cystoscopy leading to primary diagnosis. However, 
the recall bias was taken into account early in the study, 
since participants were asked to complete the questionnaire 
about the delays just after the initial cystoscopy making 
the recall bias as minimal as possible. Moreover and most 
importantly, those excluded patients did not differ signifi-
cantly from those included. Although the study can be con-
sidered as descriptive, the cohort studied can be considered 
as representative of general bladder cancer patients. The 
design of the study is a strength. The current trial is a part 
of a larger, prospective trial. In addition, no other study has 
evaluated delays in such a manner, especially the patient 
delay.
Conclusion
In our study, main delays in diagnosis of bladder cancer 
take place in specialized medical care. Never smokers and 
patients presenting with symptoms other than hematuria and 
patients referred from private outpatient clinics seem to have 
prolonged pre-consultation delays. However, we found no 
differences in delays considering age and gender.
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